Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach
V116 is projected to provide more population health benefits in Japan than PCV20, and to be cost-effective at a variety of price premiums.
Authors
- Kelly D. Johnson (ORCID: https://orcid.org/0000-0002-4275-6135)
- Atsushi Tajima (ORCID: https://orcid.org/0000-0001-9193-9934)
- Peter P. Mueller (ORCID: https://orcid.org/0000-0002-5334-0362)
- Taizo Matsuki (ORCID: https://orcid.org/0000-0002-0591-4261)
- Nicole Cossrow (ORCID: https://orcid.org/0009-0006-4982-4547)
- Kelsie Cassell (ORCID: https://orcid.org/0000-0003-0369-4186)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD K.K. (Japan) (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1080/13696998.2024.2445429
- Citations
- 6
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.32